PMV Pharma names Matt Eckler to board ahead of planned NDA filing

PMV Pharmaceuticals, Inc. announced on October 5, 2026 that Dr. Matt Eckler was appointed to its Board of Directors effective October 1, 2026, serving a term that expires at the Company's 2029 Annual Meeting of Stockholders.¹

The company said Dr. Eckler joins the board after enrollment finished in the Phase 2 monotherapy portion of the ongoing "PYNNACLE" Phase 2 pivotal trial, and as PMV Pharma prepares to submit a New Drug Application seeking accelerated approval of rezatapopt for patients with platinum-resistant or refractory ovarian cancer carrying a TP53 Y220C mutation, with that filing targeted for the first quarter of 2027.¹

Rezatapopt is described as a first-in-class small molecule p53 reactivator built to bind selectively within the pocket of the mutant p53 Y220C protein and restore wild-type tumor suppressor activity.¹ The FDA has granted the drug Fast Track designation for solid tumors bearing a p53 Y220C mutation, along with Orphan Drug Designation covering TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers.¹

Per the filing, Eckler has been a Principal at Samsara BioCapital, LLC since May 2025 and previously worked as a healthcare investor at ArrowMark Partners from May 2021 to May 2025.¹ His compensation includes $40,000 in annual cash pay for board service plus an initial stock option grant of 84,000 shares, issued on the first trading day on or after his appointment date.¹ He is also set to receive an annual option for 42,000 shares on each stockholder meeting date going forward.¹

The filing states there are no arrangements tied to Eckler's appointment and no family relationships linking him to other company directors or officers.¹